Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 28, 2015 07:30 ET | Source: SteadyMed Therapeutics

SteadyMed Announces Positive Clinical Study Results in Support of SMT-201 for the Treatment of Post Surgical Pain in the Home Setting

SAN RAMON, Calif., Oct. 28, 2015 (GLOBE NEWSWIRE) -- SteadyMed Ltd. (Nasdaq:STDY), a specialty pharmaceutical company focused on the development of drug products to treat orphan and high-value...
October 21, 2015 07:00 ET | Source: SteadyMed Therapeutics

SteadyMed Files Inter Partes Review to Invalidate United Therapeutics Patent

SAN RAMON, Calif., Oct. 21, 2015 (GLOBE NEWSWIRE) -- SteadyMed Ltd. (Nasdaq:STDY), a specialty pharmaceutical company focused on the development of drug products to treat orphan and high-value...
September 02, 2015 07:30 ET | Source: SteadyMed Therapeutics

SteadyMed to Participate in Upcoming Investor Conferences

SAN RAMON, Calif., Sept. 2, 2015 (GLOBE NEWSWIRE) -- SteadyMed Ltd. (Nasdaq:STDY), a specialty pharmaceutical company focused on the development of drug products to treat orphan and high value...
August 13, 2015 16:05 ET | Source: SteadyMed Therapeutics

SteadyMed Provides Insights on Recent Corporate Developments and Reports Second Quarter 2015 Financial Results

SAN RAMON, Calif., Aug. 13, 2015 (GLOBE NEWSWIRE) -- SteadyMed Ltd. (NASDAQ:STDY), a specialty pharmaceutical company focused on the development of drug products to treat orphan and high value...
August 06, 2015 07:30 ET | Source: SteadyMed Therapeutics

SteadyMed to Provide Insights on Recent Corporate Developments and Report Second Quarter 2015 Financial Results

SAN RAMON, Calif., Aug. 6, 2015 (GLOBE NEWSWIRE) -- SteadyMed Ltd. (Nasdaq:STDY), a specialty pharmaceutical company focused on the development of drug products to treat orphan and high value diseases...
July 07, 2015 07:00 ET | Source: SteadyMed Therapeutics

SteadyMed Completes Program of Human Factors Studies Validating Usability of Trevyent

SAN RAMON, Calif., July 7, 2015 (GLOBE NEWSWIRE) -- SteadyMed Ltd. (Nasdaq:STDY), a specialty pharmaceutical company focused on the development of drug products to treat orphan and high value diseases...
June 29, 2015 07:00 ET | Source: SteadyMed Therapeutics

SteadyMed and Cardiome Enter Into a License Agreement for the Commercialization Rights to Trevyent(R) Outside the U.S.

SAN RAMON, Calif. and VANCOUVER, Canada, June 29, 2015 (GLOBE NEWSWIRE) -- SteadyMed Ltd. (Nasdaq:STDY), a specialty pharmaceutical company focused on the development of drug products to treat orphan...
June 18, 2015 07:30 ET | Source: SteadyMed Therapeutics

SteadyMed Adds Significant Commercial Expertise to Its Board of Directors With the Appointment of Elizabeth A. Cermak

SAN RAMON, Calif., June 18, 2015 (GLOBE NEWSWIRE) -- SteadyMed Ltd. (Nasdaq:STDY), a specialty pharmaceutical company focused on the development of drug products to treat orphan and high value...
June 16, 2015 11:40 ET | Source: SteadyMed Therapeutics

SteadyMed to Present at the JMP Securities Life Sciences Conference

SAN RAMON, Calif., June 16, 2015 (GLOBE NEWSWIRE) -- SteadyMed Ltd. (Nasdaq:STDY), a specialty pharmaceutical company focused on the development of drug products to treat orphan and high value...
May 14, 2015 08:53 ET | Source: SteadyMed Therapeutics

CORRECTING and REPLACING - SteadyMed Reports Recent Developments, Financial Highlights and First Quarter 2015 Financial Results

SAN RAMON, Calif., May 14, 2015 (GLOBE NEWSWIRE) -- In a release issued under the same headline earlier today by SteadyMed Ltd. (Nasdaq:STDY), please note that in the first paragraph under the First...

keyboard_arrow_left Previous Page

Next Page keyboard_arrow_right